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Abstract 
Cancer metabolism and epigenetic alteration are two critical mechanisms for tumorigenesis and cancer progres‑
sion; however, the dynamic interplay between them remains poorly understood. As reported in the article entitled 
“Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase,” which 
was recently published in Cancer Research, our group examined the physiological role of lymphocyte‑specific heli‑
case (LSH) in nasopharyngeal carcinoma (NPC) by focusing on cancer progression and the tricarboxylic acid cycle. 
We found that LSH was overexpressed in NPC, and its expression associated with Epstein‑Barr virus infection. We 
also found that LSH directly suppressed fumarate hydratase (FH), a key component of the tricarboxylic acid cycle, in 
combination with euchromatic histone‑lysine N‑methyltransferase 2 (EHMT2), also known as G9a. Depletion of FH 
promoted epithelial‑mesenchymal transition (EMT). Moreover, LSH controlled expression of tricarboxylic acid cycle 
intermediates that promote cancer progression, including EMT, through activation by inhibitor of nuclear factor 
kappa‑B kinase alpha (IKKα), a chromatin modifier and transcriptional activator. Our study showed that LSH plays a 
critical role in cancer progression, which has important implications for the development of novel strategies to treat 
NPC.
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Background
Cancer metabolism and epigenetic alteration, especially 
in chromatin remodeling, are two critical mechanisms 
for tumorigenesis and cancer progression; however, the 
dynamic interplay between them in tumors remains 
poorly understood [1–3]. Lymphocyte-specific helicase 
(LSH), also called helicase, lymphoid-specific (HELLS), 
is a member of the ATP-dependent helicase in sucrose 
nonfermenting 2 (SNF2). LSH is not only involved in 
DNA methylation, but it also promotes PolII stalling or 
transcriptional pausing [3–5]. We confirmed that LSH 
interaction with long non-coding RNA (LncRNA) HOX 
transcript antisense RNA (HOTAIR) regulates the ratio 
of FoxA1 to FoxA2 and plays a critical role in lung cancer 
[6]. Epithelial-mesenchymal transition (EMT) is thought 
to be activated in cancer cells, linked to their dissocia-
tion from the primary tumor and their intravasation into 
blood vessels [7]. However, the effect of EMT in cancer 
progression, especially in chromatin remodeling, remains 
poorly understood. But now, based on the He et  al. 
study, “Chromatin remodeling factor LSH drives can-
cer progression by suppressing the activity of fumarate 
hydratase,” published in Cancer Research [8], the inter-
play between epigenetic controls in chromatin remod-
eling and EMT has been addressed.
Oncoprotein latent membrane protein 1 (LMP1) 
encoded by Epstein-Barr virus (EBV) infects more than 
90% of the global adult population and contributes to 
several malignancies, including nasopharyngeal carci-
noma (NPC) [9–11], which is a common cancer in South 
China and in Southeast Asia [12, 13]. Epigenetic changes 
induced by EBV and its products, such as LMP1, are 
key events in the viral process of carcinogenesis, includ-
ing transcriptional pausing [10, 14]. Chromatin remod-
eling factors are crucial factors of epigenetics and play 
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a critical role in the development of several malignan-
cies [15], but their role in the progress of NPC remains 
unknown. Recent work from our group provides robust 
evidence that LSH is highly expressed in NPC, where it 
is controlled by LMP1 [8]. Furthermore, our group found 
that LSH not only promotes growth, migration, and inva-
sion of NPC cancer cells in vitro but also links with EMT, 
including cell migration, invasion, and tumor growth and 
colonization in vivo [8], suggesting that LSH plays a criti-
cal role in tumor growth and metastasis. Based on these 
findings, it is clear that LSH promotes transition from the 
epithelial stage to the mesenchymal stage.
Altered cellular metabolism, in particular the Warburg 
effect, is a hallmark of cancer cells, with the tricarbox-
ylic acid (TCA) cycle at the center of oxidative metabo-
lism, serving as a robust source for intermediates that are 
required for anabolic reactions [16]. The mitochondrial 
enzyme fumarate hydratase (FH), a key component of the 
TCA cycle, catalyzes the hydration of fumarate to malate 
and is essential for cellular energy production and macro-
molecular biosynthesis. In studying the molecular mech-
anism and seeking to identify potential targets mediating 
the TCA cycle, our group found (using polymerase chain 
reaction array analysis) a repressive regulatory role of 
LSH in FH expression. We also confirmed that LSH is 
an important regulator of FH expression and down-reg-
ulates FH protein level in NPC derived from xenograft 
and clinical samples. We found that LSH was associ-
ated with the fh promoter; therefore, FH may serve as a 
direct target of LSH function. However, LSH may repress 
the fh promoter independent of DNA methylation, even 
though LSH is linked with DNA methylation, indicating 
that another mechanism is involved. G9a, also known as 
euchromatic histone-lysine N-methyltransferase 2, is an 
important epigenetic regulator, which monomethylates 
and dimethylates lysine-9 [17]. Our group provided the 
evidence of an interaction between LSH and G9a; the 
evidence of recruitment of G9a to the fh promoter in a 
LSH-dependent manner; and the evidence of subsequent 
chromatin modification leading to FH promoter repres-
sion [8], thus linking epigenetic regulation by LSH with 
suppression of the emerging tumor suppressor gene FH.
Oncometabolites are metabolites whose abnormal 
expression causes metabolic and epigenetic dysregula-
tion and transformation to malignancy [18]. Inactivation 
of genetic mutations alters the level of 2-oxoglutarate-
dependent oxygenases and leads to epigenetic deregula-
tion of oncogenes or tumor suppressors [18, 19]. Diverse 
metabolites serve as cofactors or substrates for enzymes 
involved in the deposition or exchange of epigenetic 
marks, initiating a metabolite-driven pathway of gene 
regulation [20]. α-Ketoglutaric acid (α-KG) has been 
shown to influence the pluripotency state in embryonic 
stem cells via alternation of multiple chromatin modifica-
tions [21]. In our study, we found that TCA cycle inter-
mediates and the ratio of α-KG/succinate and α-KG/
fumarate are regulated by LSH [8]. However, we found no 
association between the EBV status and the intermedi-
ates of TCA cycles in NPC patients.
The functional interactions between EMT-inducing 
transcription factors and the modulators of chromatin 
configuration are central to the underlying mechanism of 
cancer progression [22]. Metabolic competition can drive 
cancer progression [23], and this competition is due to 
the disturbed balance of TCA intermediates that can trig-
ger EMT. The reprogramming of gene expression during 
EMT is initiated and controlled by signaling pathways 
that respond to extracellular cues and lead to metabolic 
reprogramming. In our study, we showed that overex-
pression of LSH is linked to EMT by increasing migration 
and invasion ability in NPC [8]. This finding also indi-
cated that EMT induction by LMP1 is mediated by LSH. 
Furthermore, we found that many other key regulators 
that induce EMT, such as TWIST and Snail, are affected 
by LMP1. Moreover, TCA intermediates promote cancer 
progression through the decrease of epithelial markers 
and the increase of mesenchymal marker expression.
Recently, abnormal levels of TCA intermediates 
were shown to activate nuclear factor kappa-B (NF-κB) 
using a non-canonical pathway independent of inhibi-
tor of nuclear factor kappa-B kinase alpha (IKKα) [24]. 
Depending on the type of malignancy, IKKα can provide 
both tumor-promoting and tumor-suppressive mecha-
nisms that are, in most instances, cell autonomous. We 
recently found that IKKα is diversely expressed in kerati-
nizing and non-keratinizing carcinomas even in the same 
type of cancer [25]. In addition, we showed that IKKα can 
localize to the nucleus and that nuclear IKKα can directly 
bind to the promoters of inflammation factors and leu-
cine-rich repeat containing G-protein-coupled receptor 5 
(LGR5), a stem cell marker, thereby up-regulating LGR5 
expression through activation of signal transducer and 
activator of transcription 3 (STAT3) signaling pathway 
during cancer progression [25, 26]. The chromatin regu-
lator and transcriptional activator IKKα may be involved 
in the regulation of EMT markers, mediating the effect of 
LSH and TCA intermediates. LSH overexpression, as well 
as de-regulation of TCA intermediates, leads to IKKα 
recruitment to the promoters of EMT-related genes. In 
this way, LSH induces a cascade of epigenetic and meta-
bolic changes that result in further epigenetic regulations 
via IKKα and EMT.
Based on our findings, we propose a model for LSH-
mediated signaling and enhancement of NPC tumo-
rigenesis (Fig.  1). In this model, LSH acts as a driver 
of cancer progression, involving EMT, invasion, and 
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migration. Specifically, LSH, together with G9a, represses 
FH. Reduced FH level leads to a reduction of succinate, 
fumarate, and malate; it also increases the ratio of α-KG to 
fumarate. TCA intermediates, including α-KG and citrate, 
decrease E-cadherin and ZO-1 expression and increase 
vimentin expression. The changes of EMT marker gene 
expression are controlled by IKKα, which binds directly 
to these promoters as a chromatin bona fide modifier. The 
pathway leads to EMT, promoting migration, invasion, and 
cancer progression. However, several issues still need to be 
addressed. First, it remains unclear which signaling path-
way is involved in the regulation of LMP1 on LSH (LMP1 
is a membrane protein and LSH is a chromatin remodeling 
in the nucleus). Second, it is necessary to address how and 
why, in tumor tissues from patients, TCA intermediates 
change in high levels of LSH expression.
Conclusions
Our findings suggest that LSH acts as a driver in NPC 
by promoting EMT, cell growth, migration, and inva-
sion, which are key characteristics of cancer progression. 
Our study highlights the importance of LSH-mediated 
regulation of TCA intermediates in cancer progression. 
Repression of LSH and its downstream effects may serve 
as a potential target for novel therapeutic strategies.
Abbreviation
LMP1: latent membrane protein 1.
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Fig. 1 Schematic model of lymphocyte‑specific helicase (LSH) in cancer progression. LSH promotes cell growth, migration, and invasion, which 
are characteristics of cancer progression. The effect of LSH is, in part, mediated by fumarate hydratase (FH), through the intact combination of LSH 
and euchromatic histone‑lysine N‑methyltransferase 2 (G9a). FH repression, in turn, leads to changes of tricarboxylic acid cycle (TCA) intermediates, 
including succinate, fumarate, and malate, and an increase in the ratio of α‑ketoglutarate (α‑KG) to fumarate. TCA intermediates promote migra‑
tion, invasion, and epithelial‑mesenchymal transition (EMT) through the decrease of E‑cadherin and tight junction protein ZO‑1 and the increase of 
vimentin. The changes of E‑cadherin and ZO‑1 are mediated by inhibitor of nuclear factor kappa‑B kinase alpha (IKKα), which directly binds to these 
promoters
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